Wagner, A. J., Riedel, R. F., Van Tine, B. A., Chugh, R., Ganjoo, K. N., Cranmer, L. D., … Dickson, M. A. (2018). Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa). In Journal of Clinical Oncology (Vol. 36, pp. TPS11589–TPS11589). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps11589

Wagner, Andrew J., Richard F. Riedel, Brian Andrew Van Tine, Rashmi Chugh, Kristen N. Ganjoo, Lee D. Cranmer, Seth Pollack, et al. “Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).” In Journal of Clinical Oncology, 36:TPS11589–TPS11589. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps11589.

Wagner AJ, Riedel RF, Van Tine BA, Chugh R, Ganjoo KN, Cranmer LD, et al. Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS11589–TPS11589.

Wagner, Andrew J., et al. “Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS11589–TPS11589. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps11589.

Wagner AJ, Riedel RF, Van Tine BA, Chugh R, Ganjoo KN, Cranmer LD, Pollack S, Sankhala KK, Gordon EM, Ravi V, Hornick JL, Kwiatkowski DJ, Grigorian B, Desai N, Dickson MA. Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS11589–TPS11589.